Table III.
Uni and multivariate analysis displaying the HR for mortality.
| Variable | Univariate HR (95% CI) | P-value | Multivariate HR (95%CI) | P-value |
|---|---|---|---|---|
| Sex | ||||
| Male (reference) | ||||
| Female | 0.69 (0.38-1.25) | 0.20 | 0.54 (0.28-1.02) | 0.06 |
| Age | ||||
| Continuous variable | 0.99 (0.96-1.02) | 0.40 | 0.98 (0.94-1.01) | 0.20 |
| Site of primary | ||||
| Colon (reference) | ||||
| Rectum | 0.89 (0.48-1.68) | 0.70 | 0.90 (0.48-1.70) | 0.70 |
| Performance status | ||||
| 0 (reference) | ||||
| 1 | 5.74 (2.24-14.74) | <0.01 | 2.19 (0.74-6.43) | 0.15 |
| 2 | 13.63 (2.84-65.52) | 0.01 | 3.84 (0.51-28.91) | 0.19 |
| cfDNA (baseline) | ||||
| Continous variable | 2.39 (1.51-3.76) | <0.01 | 1.90 (1.07-3.38) | 0.03 |
| CEA (baseline) | ||||
| Continous variable | 1.49 (0.70-3.18) | 0.3 | 1.01 (0.45-2.23) | 0.90 |
| KRAS status | ||||
| Wild-type (reference) | ||||
| Mutated | 2.93 (1.66-5.18) | <0.01 | 3.17 (1.67-6.03) | <0.01 |
cfDNA, cell free DNA; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; KRAS, kirsten RAt sarcoma oncogene.